ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1904

Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs

Douglas White1, Maya Buch2, Suzanne Murray3, Diane Caballero4, Orsolya Nagy5 and Tsutomu Takeuchi6, 1Waikato Clinical School, University of Auckland, Hamilton, New Zealand, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 3AXDEV Group Inc, Brossard, QC, Canada, 4AbbVie, Inc., Chicago, IL, 5AbbVie, Inc., Budapest, Hungary, 6Keio University School of Medicine and Saitama Medical University, Tokyo, Japan

Meeting: ACR Convergence 2023

Keywords: Clinical practice guidelines, quality of care, rheumatoid arthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1895–1912) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Treat-to-target (T2T) is a widely established and accepted approach in RA management, but its real-world implementation is suboptimal1. Further primary research is required to identify the most relevant barriers to, and facilitators of, real-world T2T implementation2. This survey assessed perceived barriers to, and facilitators of, T2T implementation among rheumatologists globally.

Methods: A non-remunerated quantitative survey was completed by eligible rheumatologists (≥2 years’ practice experience, awareness of T2T approach, ≥10 patients with RA/year) between June 6 and Sep 30, 2022, in 35 ex-US countries. The survey was informed by a systematic literature review2 and included 9 questions across 6 key areas of T2T implementation in RA: knowledge, skill, confidence, agreement (attitudes/context), contextual/systemic barriers, and behaviors. Knowledge, skill, and confidence were rated on a 5-point scale and reported as suboptimal (no/basic/intermediate knowledge or skill; not/slightly/somewhat confident) or optimal (advanced/expert knowledge or skill; confident/very confident). Agreement was rated on a 6-point scale (strongly disagree to strongly agree) and barriers on a 4-point scale (not at all to serious barrier). Behaviors were rated on a 5-point scale and reported as infrequent (never/rarely/sometimes) or frequent (often/always).

Results: Of 903 surveyed rheumatologists (Europe, n=297; Americas, n=293; Asia-Pacific, n=200; Middle East & Africa, n=113), 72% had ≥11 years of practice experience and 80% reported practicing T2T consistently or frequently. Despite awareness of the T2T approach, there was suboptimal knowledge, skill, and confidence in determining patient health literacy and adapting language while communicating with patients, considering patient goals, and using PROs to assess disease activity. At least 75% of rheumatologists never, rarely, or sometimes used telehealth or encouraged patients to use disease self-assessment tools (Figure 1). The least frequently used tools by rheumatologists were self-reflection questionnaires, treatment considerations checklists, case scenarios, and shared decision-making tools (Figure 2), primarily due to the perception these tools were time-consuming, not needed, or non-existent. Patient adherence-related issues were the top barriers to documenting disease activity, with the other barriers mostly related to healthcare system-related processes. Higher gaps were generally observed in rheumatologists who do not consistently or frequently practice T2T, or who had < 10 years of experience. Table 1 regroups the common gaps and barriers under 4 key themes.

Conclusion: These results highlight practice gaps and educational needs in rheumatologists that can inform educational programs and interventions to support T2T implementation. Based on these findings, recommended focus areas for improving T2T implementation include incorporating all components of T2T in practice, optimal use of telehealth in RA, patient education and shared decision-making, and the use of tools to enhance practice efficiency.

References:

  1. Yu Z, et al. Arthritis Care Res 2018;70:801–6
  2. Gossec L, et al. Ann Rheum Dis 2022;81:572 [POS0607]

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. White: AbbVie, 2, 6, Novartis, 1, 2; M. Buch: AbbVie, 2, 6, 12, All paid to host institution, Boehringer Ingelheim, 2, 6, 12, Paid to host institution, Galapagos, 2, 6, 12, Paid to host institution, Gilead, 2, 5, 6, 12, Paid to host institution, Lilly, 2, 6, 12, All paid to host institution, National Insitute for Health and Care Research (NIHR), 3, 12, Maya H Buch is a National Institute for Health and Care Research (NIHR) Senior Investigator. The views expressed are those of the authors and not nece, Pfizer, 2, 12, Paid to host institution; S. Murray: AXDEV Group Inc, 12, CEO and founder; D. Caballero: AbbVie, 3, 11; O. Nagy: AbbVie, 3, 11; T. Takeuchi: AbbVie, 2, 5, 6, AYUMI, 5, Bristol-Myers Squibb, 6, Chugai, 2, 5, 6, Daiichi Sankyo, 5, Eisai, 5, 6, Eli Lilly Japan, 2, 6, Gilead, 2, 6, Janssen, 6, Mitsubishi-Tanabe, 2, 5, 6, ONO, 5, Pfizer Japan, 6, Taiho, 2.

To cite this abstract in AMA style:

White D, Buch M, Murray S, Caballero D, Nagy O, Takeuchi T. Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/treat-to-target-in-ra-clinical-practice-global-evidence-of-practice-gaps-and-educational-needs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-in-ra-clinical-practice-global-evidence-of-practice-gaps-and-educational-needs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology